Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study
The Journal of Dermatology · 2026
DOI: 10.1111/1346-8138.70431 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2026. Verfasst von Fatich Memet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye. Hauptthemen laut MEDLINE: Mycosis Fungoides, Bexarotene, Skin Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Topical bexarotene 1% gel is an approved skin‐directed treatment for refractory or persistent stage IA‐IB cutaneous T‐cell lymphoma, but real‐world evidence in mycosis fungoides (MF), particularly regarding maintenance use after complete response, remains limited. We retrospectively reviewed 56 patients with histopathologically and immunohistochemically confirmed, previously treated stage IA‐IB MF who received topical bexarotene between 2009 and 2022. Clinical response, post‐treatment biopsy findings, adverse events, maintenance therapy, and relapse outcomes were analyzed. The cohort included 31 women and 25 men; 42 patients (75.0%) had stage IA and 14 (25.0%) had stage IB disease. Complete response (CR) was achieved in 20 patients (35.7%) and partial response in 15 (26.8%), yielding an overall response rate of 62.5%. Overall response was higher in stage IA than in stage IB disease (73.8% vs. 28.6%; p = 0.003) and in T1a than in T2a disease (77.1% vs. 36.4%; p = 0.044). All biopsied complete responders showed no MF‐compatible histology. Adverse events were exclusively local and manageable. Among 18 evaluable complete responders, relapse occurred in 15 (83.3%). Median time to relapse was longer with maintenance topical bexarotene than without maintenance (45 vs. 30 weeks; p = 0.039). Topical bexarotene appears effective and well tolerated in previously treated stage IA‐IB MF, with greatest benefit in limited patch‐stage disease. Maintenance use after CR may delay relapse, but this exploratory finding requires prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye.
ORCID-Profile: Fatich Memet, Dilek Bayramgürler, Abdullah Demirbaş, Evren Odyakmaz Demirsoy, Aysun Şikar Aktürk, Rebiay Kıran
Zitieren
APA
Memet, F., Bayramgürler, D., Demirbaş, A., Demirsoy, E. O., Aktürk, A. Ş., Sayman, N., & Kıran, R. (2026). Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.70431
Vancouver
Memet F, Bayramgürler D, Demirbaş A, Demirsoy EO, Aktürk AŞ, Sayman N, et al. Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study. The Journal of Dermatology. 2026. doi:10.1111/1346-8138.70431
BibTeX
@article{Memet2026,
author = {Memet, Fatich and Bayramgürler, Dilek and Demirbaş, Abdullah and Demirsoy, Evren Odyakmaz and Aktürk, Aysun Şikar and Sayman, Nilgün and Kıran, Rebiay},
title = {Efficacy, Safety, and Maintenance Use of Topical Bexarotene in Early‐Stage Mycosis Fungoides: A Single‐Center Retrospective Real‐World Study},
journal = {The Journal of Dermatology},
year = {2026},
doi = {10.1111/1346-8138.70431}
}
EUVIMED